Role of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain in the immune mechanism of autoimmune hepatitis and its prospects in treatment

Lin HAN; Mingyue ZHANG; Ying SUN

doi:10.3969/j.issn.1001-5256.2022.03.034

Volume 38 Issue 3

Mar. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(3): 656-659

PDF( 1884 KB)

Role of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain in the immune mechanism of autoimmune hepatitis and its prospects in treatment

DOI: 10.3969/j.issn.1001-5256.2022.03.034

Lin HAN¹,
Mingyue ZHANG^{1, 2},
Ying SUN^{1, 2
,
,
,}

1.
Department of Liver Disease, Senior Department of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China
2.
Graduate School, Medical School of Chinese PLA, Beijing 100039, China

Research funding:

General Project of National Natural Science Foundation of China (82170538)

More Information

Corresponding author: SUN Ying, sunying_302@yahoo.com(ORCID: 0000-0002-2570-9206)
Received Date: 2021-07-22
Accepted Date: 2021-09-27
Published Date: 2022-03-20

Abstract

Abstract

The imbalance of immune tolerance plays a key role in the pathogenesis of autoimmune hepatitis (AIH), and the abnormal expression of coinhibitory signal molecules for regulatory T cells (Treg) may be one of the important reasons for the destruction of autoantigen tolerance. As a coinhibitory signal molecule, T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is an inhibitory receptor mainly expressed on Treg. This article elaborates on the immune mechanism of Treg associated with AIH and the role of TIGIT in the development, progression, and treatment of autoimmune diseases, so as to find the treatment strategy with TIGIT as the candidate target for AIH.
- Hepatitis, Autoimmune,
- Therapeutics,
- TIGIT

FullText(HTML)

References(27)

References

[1]	MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
[2]	WANG QX, MA X. Current status and perspectives of autoimmune hepatitis[J]. J Clin Hepatol, 2020, 36(4): 721-723. DOI: 10.3969/j.issn.1001-5256.2020.04.001. 王绮夏, 马雄. 自身免疫性肝炎的研究现状与展望[J]. 临床肝胆病杂志, 2020, 36(4): 721-723. DOI: 10.3969/j.issn.1001-5256.2020.04.001.
[3]	LONGHI MS, MIELI-VERGANI G, VERGANI D. Regulatory T cells in autoimmune hepatitis: An updated overview[J]. J Autoimmun, 2021, 119: 102619. DOI: 10.1016/j.jaut.2021.102619.
[4]	WANG H, FENG X, YAN W, et al. Regulatory T cells in autoimmune hepatitis: Unveiling their roles in mouse models and patients[J]. Front Immunol, 2020, 11: 575572. DOI: 10.3389/fimmu.2020.575572.
[5]	CHAUVIN JM, ZAROUR HM. TIGIT in cancer immunotherapy[J]. J Immunother Cancer, 2020, 8(2): e000957. DOI: 10.1136/jitc-2020-000957.
[6]	JI W, PENG X, LOU T, et al. Total flavonoids from Tetrastigma hemsleyanum ameliorates inflammatory stress in concanavalin A-induced autoimmune hepatitis mice by regulating Treg/Th17 immune homeostasis[J]. Inflammopharmacology, 2019, 27(6): 1297-1307. DOI: 10.1007/s10787-019-00599-0.
[7]	WU HY, YANG JL. TIGIT and anti-tumor immunity[J]. Chin J Immunol, 2020, 36(11): 1407-1408, inside back cover. DOI: 10.3969/j.issn.1000-484X.2020.11.025. 吴红艳, 杨建林. TIGIT与抗肿瘤免疫[J]. 中国免疫学杂志, 2020, 36(11): 1407-1408, 封3. DOI: 10.3969/j.issn.1000-484X.2020.11.025.
[8]	YANG ZZ, KIM HJ, WU H, et al. TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma[J]. Clin Cancer Res, 2020, 26(19): 5217-5231. DOI: 10.1158/1078-0432.CCR-20-0558.
[9]	ANDERSON AC, JOLLER N, KUCHROO VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation[J]. Immunity, 2016, 44(5): 989-1004. DOI: 10.1016/j.immuni.2016.05.001.
[10]	ZHOU H, LI B, LI J, et al. Dysregulated T cell activation and aberrant cytokine expression profile in systemic lupus erythematosus[J]. Mediators Inflamm, 2019, 2019: 8450947. DOI: 10.1155/2019/8450947.
[11]	LIU S, SUN L, WANG C, et al. Treatment of murine lupus with TIGIT-Ig[J]. Clin Immunol, 2019, 203: 72-80. DOI: 10.1016/j.clim.2019.04.007.
[12]	DENG C, LI W, FEI Y, et al. Imbalance of the CD226/TIGIT immune checkpoint is involved in the pathogenesis of primary biliary cholangitis[J]. Front Immunol, 2020, 11: 1619. DOI: 10.3389/fimmu.2020.01619.
[13]	AKIYAMA M, SUZUKI K, YOSHIMOTO K, et al. Peripheral TIGIT⁺ T follicular helper cells that produce high levels of interleukin-21 via OX40 represent disease activity in IgG4-related disease[J]. Front Immunol, 2021, 12: 651357. DOI: 10.3389/fimmu.2021.651357.
[14]	NAGAI K. Co-inhibitory receptor signaling in T-cell-mediated autoimmune glomerulonephritis[J]. Front Med (Lausanne), 2020, 7: 584382. DOI: 10.3389/fmed.2020.584382.
[15]	PING YQ, MAO C, XIAO P, et al. Structures of the glucocorticoid-bound adhesion receptor GPR97-Go complex[J]. Nature, 2021, 589(7843): 620-626. DOI: 10.1038/s41586-020-03083-w.
[16]	BUTTGEREIT F, GABER T. New insights into the fascinating world of glucocorticoids: The dexamethasone-miR-342-Rictor axis in regulatory T cells[J]. Cell Mol Immunol, 2021, 18(3): 520-522. DOI: 10.1038/s41423-020-00598-0.
[17]	WANG R, WANG QX, MA X. Standard therapy and potential therapeutic targets for autoimmune hepatitis[J]. J Clin Hepatol, 2020, 36(4): 737-742. DOI: 10.3969/j.issn.1001-5256.2020.04.005. 王睿, 王绮夏, 马雄. 自身免疫性肝炎的标准治疗和潜在治疗靶点[J]. 临床肝胆病杂志, 2020, 36(4): 737-742. DOI: 10.3969/j.issn.1001-5256.2020.04.005.
[18]	LONGHI MS, MA Y, BOGDANOS DP, et al. Impairment of CD4(+) CD25(+) regulatory T-cells in autoimmune liver disease[J]. J Hepatol, 2004, 41(1): 31-37. DOI: 10.1016/j.jhep.2004.03.008.
[19]	TAUBERT R, HARDTKE-WOLENSKI M, NOYAN F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies[J]. J Hepatol, 2014, 61(5): 1106-1114. DOI: 10.1016/j.jhep.2014.05.034.
[20]	BUITRAGO-MOLINA LE, PIETREK J, NOYAN F, et al. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis[J]. J Autoimmun, 2021, 117: 102591. DOI: 10.1016/j.jaut.2020.102591.
[21]	LAPIERRE P, BÉLAND K, YANG R, et al. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance[J]. Hepatology, 2013, 57(1): 217-227. DOI: 10.1002/hep.26023.
[22]	XIA G, WU S, WANG X, et al. Inhibition of microRNA-155 attenuates concanavalin-A-induced autoimmune hepatitis by regulating Treg/Th17 cell differentiation[J]. Can J Physiol Pharmacol, 2018, 96(12): 1293-1300. DOI: 10.1139/cjpp-2018-0467.
[23]	HARDTKE-WOLENSKI M, TAUBERT R, NOYAN F, et al. Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigens[J]. Hepatology, 2015, 61(4): 1295-1305. DOI: 10.1002/hep.27639.
[24]	LONGHI MS, HUSSAIN MJ, KWOK WW, et al. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis[J]. Hepatology, 2011, 53(2): 536-547. DOI: 10.1002/hep.24039.
[25]	VUERICH M, HARSHE R, FRANK LA, et al. Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis[J]. J Hepatol, 2021, 74(1): 48-57. DOI: 10.1016/j.jhep.2020.06.044.
[26]	RAFFIN C, VO LT, BLUESTONE JA. Treg cell-based therapies: Challenges and perspectives[J]. Nat Rev Immunol, 2020, 20(3): 158-172. DOI: 10.1038/s41577-019-0232-6.
[27]	LUCCA LE, AXISA PP, SINGER ER, et al. TIGIT signaling restores suppressor function of Th1 Tregs[J]. JCI Insight, 2019, 4(3): e124427. DOI: 10.1172/jci.insight.124427.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (524) PDF downloads(53)

Role of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain in the immune mechanism of autoimmune hepatitis and its prospects in treatment

DOI: 10.3969/j.issn.1001-5256.2022.03.034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain in the immune mechanism of autoimmune hepatitis and its prospects in treatment

DOI: 10.3969/j.issn.1001-5256.2022.03.034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content